news
NHS releases guidance to remove drugs from prescription list
Seven medications have been suggested for removal from prescriptions by the NHS after a public consultation.
List view / Grid view
Atrial Fibrillation
news
Oral anticoagulants and antiplatelets linked to poor outcome in atrial fibrillation
The results challenged the use of combined oral anticoagulant and antiplatelet therapy in patients with atrial fibrillation, especially those without an indication for antiplatelet therapy.
news
New anti-clotting drugs linked to lower risk of serious bleeding
Direct oral anticoagulants (DOACs) used to treat serious blood clots are associated with reduced risks of major bleeding compared with the older anti-clotting drug, warfarin, finds a new study.
news
Anticoagulant drugs appear to reduce the risk of stroke in patients with AF
Blood-thinning drugs not only reduce the risk of stroke in patients with AF but are also associated with a significant reduction in the risk of dementia...
news
Atrial fibrillation market will peak at $11.8 billion in 2022
2 August 2016 | By GlobalData
The atrial fibrillation market will expand from approximately $8 billion in 2015 to hit its peak of $11.8 billion in 2022, after which the impact of patent expiries will see the market value fall rapidly to $4.9 billion by 2025, according to research and consulting firm GlobalData...
news
Daiichi Sankyo helps raise awareness of VTE and AF
13 October 2015 | By Daiichi Sankyo
Daiichi Sankyo has teamed up with World Thrombosis Day to promote awareness of thrombosis, its causes, risk factors, and signs and symptoms...
news
Daiichi Sankyo’s edoxaban launched in the UK
10 July 2015 | By Victoria White
Edoxaban, a new blood-thinning drug therapy to help prevent stroke in patients with non-valvular atrial fibrillation, has been launched in the UK...
news
Swissmedic approves Lixiana for the prevention of stroke and systemic embolism in non-valvular atrial fibrillation
15 April 2015 | By Daiichi Sankyo
Swissmedic has granted approval of Lixiana for the prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation...
news
Many AF patients at high risk of stroke fail to receive guideline-recommended oral anticoagulant treatment
17 March 2015 | By Victoria White
AF patients considered at high risk for stroke may not be receiving recommended treatment as revealed in analyses from the GLORIA™-AF Registry Program...
news
U.S. FDA approves Daiichi Sankyo’s once-daily SAVAYSA™ (edoxaban) tablets for reduction of stroke risk
9 January 2015 | By Daiichi Sankyo
U.S. FDA approves Daiichi Sankyo’s once-daily SAVAYSA™ (edoxaban) tablets for reduction of stroke risk in non-valvular atrial fibrillation and for the treatment of venous thromboembolism...
news
Daiichi Sankyo launches new formulation of LIXIANA® 60 mg Tablets (edoxaban) in Japan
8 December 2014 | By Daiichi Sankyo
Daiichi Sankyo Company, Limited announced that it has launched a new formulation of LIXIANA®60 mg Tablets...
news
Portola, Bristol-Myers Squibb and Pfizer announce statistically significant results from the first part of the Phase 3 ANNEXA™-A studies of investigational Andexanet Alfa with Eliquis (apixaban)
18 November 2014 | By Bristol-Myers Squibb Company
Bristol-Myers Squibb Company and Pfizer Inc. announced results from the first part of the Phase 3 ANNEXA™-A (Andexanet Alfa a Novel Antidote to the Anticoagulant Effects of fXA Inhibitors – Apixaban) studies...
news
Pradaxa® (dabigatran etexilate) now approved in more than 100 countries for stroke prevention in atrial fibrillation
6 March 2014 | By Boehringer Ingelheim
More than 100 countries have now approved Boehringer Ingelheim’s Pradaxa® for the prevention of stroke and systemic embolism for adult patients with the most common sustained heart rhythm condition...
news
Daiichi Sankyo submits SAVAYSA(TM) (edoxaban) tablets New Drug Application to the U.S. FDA
9 January 2014 | By Daiichi Sankyo
Submission based on the two largest comparative phase 3 clinical trials of a novel oral anticoagulant in patients with non-valvular atrial fibrillation or symptomatic venous thromboembolism...
news
Daiichi Sankyo submits supplemental New Drug Application in Japan for LIXIANA® (Edoxaban Tosilate Hydrate) for new indications
19 December 2013 | By Daiichi Sankyo Company
Daiichi Sankyo is seeking approval in Japan for edoxaban in new indications for non-valvular atrial fibrillation (AF) and symptomatic venous thromboembolism...
